Biotech Venture Fund's Portfolio Company, Infectex, Enrolls First Multi-Drug Resistant (MDR-TB) Patients in Pivotal Clinical Trial of SQ109, Licensed From Sequella, Inc.
12/19/2012 9:50:54 AM
More...
|
Maxwell Biotech Venture Fund's Portfolio Company, Infectex, Receives Russian Regulator's Approval to Conduct Pivotal Clinical Trial for Sequella, Inc.'s Antibiotic, SQ109, for Tuberculosis
7/26/2012 9:54:00 AM
More...
|
Sequella, Inc. Licenses Rights to Commercialize SQ109 for Tuberculosis in Russia to Maxwell Biotech Venture Fund Subsidiary; Deal Valued at Over $100 Million to the Parties
4/25/2011 9:52:49 AM
More...
|
Sequella, Inc. Awarded $4.6 Million in New National Institutes of Health (NIH) Grants to Expand Anti-Infectives Pipeline
4/4/2011 9:14:18 AM
More...
|
John H. Friedman of Easton Capital Investment Group Joins Sequella, Inc. Board of Directors
1/31/2011 9:13:30 AM
More...
|
Sequella, Inc. Files IND and Receives FDA Go-ahead for Phase 2 Trial of SQ109 in Helicobacter pylori-associated Duodenal Ulcers
12/6/2010 11:33:29 AM
More...
|
Sequella, Inc. Receives International Support for Phase 2 Clinical Trials of SQ109, its Lead Antitubercular Drug Candidate
10/18/2010 12:00:32 PM
More...
|
Sequella, Inc.: Two New Tuberculosis (TB) Drugs Show Significant Synergy In Vitro
7/26/2010 11:11:26 AM
More...
|
Sequella, Inc. and National Institutes of Health (NIH) Sign Exclusive Worldwide Licensing Agreement for SQ109 for New Infectious Disease Indications
11/17/2009 9:58:39 AM
More...
|
Sequella, Inc. Obtains Funding to Continue Expansion of its Anti-infectives Pipeline
10/12/2009 8:04:24 AM
More...
|
|